Invention Grant
US08835468B2 N-(2-(hetaryl)aryl)arylsulfonamides and n-(2-(hetaryl)hetaryl) arylsulfonamides
有权
N-（2-（杂芳基）芳基）芳基磺酰胺和正 - （2-（杂芳基）杂芳基）芳基磺酰胺
- Patent Title: N-(2-(hetaryl)aryl)arylsulfonamides and n-(2-(hetaryl)hetaryl) arylsulfonamides
- Patent Title (中): N-（2-（杂芳基）芳基）芳基磺酰胺和正 - （2-（杂芳基）杂芳基）芳基磺酰胺
-
Application No.: US13462393Application Date: 2012-05-02
-
Publication No.: US08835468B2Publication Date: 2014-09-16
- Inventor: Trevor T. Charvat , Cheng Hu , Anita Melikian , Aaron Novack , Andrew M. K. Pennell , Edward J. Sullivan , William D. Thomas , Solomon Ungashe , Penglie Zhang , Jay Powers , Sreenivas Punna
- Applicant: Trevor T. Charvat , Cheng Hu , Anita Melikian , Aaron Novack , Andrew M. K. Pennell , Edward J. Sullivan , William D. Thomas , Solomon Ungashe , Penglie Zhang , Jay Powers , Sreenivas Punna
- Applicant Address: US CA Mountain View
- Assignee: ChemoCentryx, Inc.
- Current Assignee: ChemoCentryx, Inc.
- Current Assignee Address: US CA Mountain View
- Agency: Brinks Gilson & Lione
- Agent Ryan L. Marshall
- Main IPC: A01N43/64
- IPC: A01N43/64 ; A61K31/41 ; A61K31/415 ; A01N43/56
Abstract:
Compounds are provided that act as potent antagonists of the CCR9 receptor. Animal testing demonstrates that these compounds are useful for treating inflammation, a hallmark disease for CCR9. The compounds are generally aryl sulfonamide derivatives and are useful in pharmaceutical compositions, methods for the treatment of CCR9-mediated diseases, and as controls in assays for the identification of CCR9 antagonists.
Public/Granted literature
- US20120245138A1 N-(2-(HETARYL)ARYL)ARYLSULFONAMIDES AND N-(2-(HETARYL)HETARYL ARYLSULFONAMIDES Public/Granted day:2012-09-27
Information query
IPC分类:
